Tag
A clear, clinician-focused summary of the 2026 EAPCI/EBC consensus recommending routine intravascular imaging (IVUS/OCT) to plan, guide and optimize left main bifurcation PCI — with practical steps, controversies and implementation advice.
This updated meta-analysis of 28 RCTs reveals significant reductions in cardiovascular events and mortality with intracoronary imaging-guided PCI versus angiography-guided PCI, highlighting the importance of lesion and geographic factors in
This meta-analysis reveals significant geographic differences in the benefits of intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI), with East Asian populations showing marked reductions in cardiac death and adv
The FAVOR III China trial demonstrates that QFR-guided percutaneous coronary intervention significantly reduces major adverse cardiac events over 5 years, mainly by decreasing myocardial infarction and ischemia-driven revascularization comp
The NATURE trial demonstrates that stent retriever thrombectomy combined with conventional PCI significantly reduces infarct size in STEMI patients with large thrombus burden, without increasing short-term adverse events.
This article explores the latest evidence on antithrombotic therapy after PCI in patients with atrial fibrillation, highlighting the balance between bleeding risk and prevention of ischemic events.
The ORBITA-CTO multicenter, randomized, placebo-controlled trial demonstrates that PCI significantly improves angina symptoms and quality of life in patients with single-vessel CTO without bystander disease, compared to placebo.
The TUXEDO-2 trial demonstrated that ultra-thin strut biodegradable polymer sirolimus-eluting stents are noninferior to durable polymer everolimus-eluting stents in diabetic patients with multivessel coronary artery disease at 1-year follow
A large randomized trial found sirolimus-eluting balloon with provisional stenting noninferior to routine DES at 1 year by intention-to-treat analysis, though repeat revascularization was slightly higher and per-protocol noninferiority was
This review synthesizes the TAILORED-CHIP trial results with recent evidence on antiplatelet modulation, highlighting the challenges of balancing ischemic and bleeding risks in high-risk PCI populations.
ORBITA-2 reveals PCI’s superior placebo-controlled angina relief in focal vs. diffuse coronary artery disease, with physiological disease patterns guiding treatment decisions.
A pooled analysis of EUROCTO and DECISION-CTO trials found PCI significantly improved quality of life, angina frequency, and SAQ scores compared to medical therapy for patients with chronic total coronary occlusions, with no increased risk
A multicenter IVUS study demonstrates that rotational atherectomy significantly reduces target lesion revascularization in coronary calcified nodules. Crucially, this benefit is highly dependent on the presence of contralateral calcificatio
A landmark analysis from the NEOMINDSET trial demonstrates that while potent P2Y12 inhibitor monotherapy reduces bleeding, it significantly increases ischemic risk in the first 30 days after PCI for acute coronary syndrome, suggesting that
OCT-guided PCI enhances procedural outcomes and reduces adverse events in complex and calcified coronary lesions compared with angiography guidance, with emerging physiological assessment tools improving prognostic accuracy.
In the ADAPT AF‑DES randomized trial, NOAC monotherapy in AF patients with drug‑eluting stents implanted ≥1 year earlier reduced bleeding and was noninferior—and numerically superior—for a composite of ischemic and bleeding outcomes versus
The iMODERN trial demonstrates that immediate iFR-guided PCI of nonculprit lesions in STEMI patients offers no significant benefit over deferred stress MRI-guided PCI regarding major cardiac events at 3 years.
Reduced left ventricular ejection fraction (LVEF) adversely affects survival and myocardial infarction risk in patients with chronic kidney disease undergoing percutaneous coronary intervention, despite no significant difference in overall
The FLAVOUR trial’s extended 6.3-year follow-up shows equivalent long-term outcomes for FFR- and IVUS-guided PCI strategies in intermediate coronary stenosis, with FFR associated with fewer total PCIs but slight increases in late reva
The 10-year DANAMI-3-DEFER study compared deferred stenting to immediate stenting in STEMI, showing no mortality benefit but reduced heart failure hospitalizations with deferred stenting.
